Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for HWK-007 in NSCLC, ovarian, endometrial cancers. The expected timing is based on the latest available company guidance and may change.
10/24/25– Presented real-world analysis. IND filing planned by YE. 01/08/26:- IND cleared; Ph1 HWK-007-101 now recruiting in NSCLC, ovarian, endometrial cancers; initial data Early 2027. 03/12/26:- Ph1 HWK-007-101 trial actively recruiting in NSCLC, ovarian, endometrial; initial Ph1 data expected H1 2027. 03/17/26:- Preclinical HWK-007 poster at AACR 2026 on April 21, 2026. 05/07/26:- Ph1 HWK-007-101 (NCT07444814) enrollment ongoing; initial results still expected in H1 2027. 08/06/26:- Ph1 HWK-007-101 enrollment continues; initial results expected H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.